What are the clinical presentation, diagnostic methods, and recommended management for human infection with Shamonda virus (SHAV)?

Shamonda virus (SHAV): human disease—what to look for, how to test, what to do

Bold recommendation: Suspect SHAV only after excluding common arboviral and travel-related causes of fever/encephalitis, test with orthobunyavirus RT-PCR/serology on blood/CSF when exposure to Culicoides/mosquitoes in endemic settings is plausible, and manage supportively with strict vector avoidance—there is no proven antiviral or vaccine and morbidity/mortality hinge on early recognition of severe neurologic disease and complications. 1

• Evidence strengths/limits:
  • No human SHAV clinical trials or guidelines; human disease is inferred from closely related Simbu serogroup orthobunyaviruses and veterinary/entomologic detections. Use travel/arboviral guidelines to frame triage and differential while recognizing rarity. 1
  • Recent high‑quality reports confirm SHAV circulation in animals and vectors (Africa, Japan; reassortants in midges; emergence in European cattle 2026), supporting zoonotic exposure risk but not defining human clinical severity. Prioritize caution. 2, 3, 4, 5, 6

1) Clinical presentation (prioritize threats to morbidity/mortality/QOL)

• Typical: nonspecific febrile illness after bites from Culicoides/mosquitoes in regions with Simbu serogroup activity; incubation likely 2–10 days (by analogy to arboviruses). Severe disease in humans is unproven; anticipate spectrum similar to other orthobunyaviruses:
  • Systemic fever, headache, myalgias; usually self‑limited. 1
  • Rare but high‑impact complications to watch for: encephalitis/meningoencephalitis (altered mental status, focal deficits, seizures), hemorrhagic manifestations, or myocarditis—prompt escalation reduces mortality/QOL loss. Exclude more common etiologies first (dengue, chikungunya, rickettsioses, JE, WNV). 1
• Exposure cues that increase pretest probability:
  • Recent travel or residence in sub‑Saharan Africa or areas with Simbu serogroup detections; proximity to ruminant livestock; Culicoides midge or mosquito bites; local veterinary reports of Simbu-like outbreaks or abortions/congenital defects in ruminants. 2, 4, 5, 6

Common pitfalls:

• Anchoring on SHAV without ruling out dengue/chikungunya/rickettsioses (more morbid and common in travelers). Always exclude these first to reduce mortality. 1

2) Diagnostic approach (stepwise, actionable)

• Immediate rule‑outs with highest impact on morbidity/mortality:
  • Dengue and chikungunya PCR/Ag/serology; malaria smears/rapid tests if exposure possible; rickettsial coverage if eschar/rash and safari exposure. 1
• If orthobunyavirus/SHAV suspected (compatible exposure plus negative common panels or neuroinvasive disease):
  • Collect during acute illness:
    • Blood (serum/plasma) for orthobunyavirus/Simbu serogroup RT‑PCR and acute serology (IgM/IgG). If neurologic disease, add CSF RT‑PCR and serology; consider paired convalescent serology at 2–4 weeks. Use reference or national labs able to type Simbu serogroup (S, M, L segments). [Supported by arboviral diagnostic principles; apply enterovirus sampling logic to sample broadly when CSF PCR may be negative in CNS disease.] 1, 7
    • If available, test a panel that can differentiate SHAV from related Simbu viruses and detect reassortants (documented between Shuni, Shamonda, Caimito, Sango), as segment reassortment can mislead single‑segment assays. 3, 4, 5
  • Epidemiology support:
    • Liaise with public health if livestock outbreaks or veterinary positives are reported locally (e.g., 2026 European cattle emergence). 2
• Interpretation caveats:
  • Low viremia may yield negative PCR; seroconversion on paired sera strengthens diagnosis. Cross‑reactivity within Simbu serogroup is possible—seek genomic confirmation when feasible. 4, 5, 6

3) Management (prioritize mortality/QOL)

• There is no approved antiviral or vaccine for SHAV; treat supportively based on severity.
  • Outpatient, mild febrile illness: antipyretics, hydration; strict vector bite prevention to avoid other arboviral coinfections. 1
  • Suspected/confirmed neuroinvasive disease: hospitalize; seizure control, airway protection, intracranial pressure management per encephalitis protocols; escalate monitoring to ICU if rapid deterioration. Early supportive care reduces morbidity/mortality as per arboviral encephalitis principles. 1
• Avoid empiric therapies with risk > benefit:
  • No evidence for ribavirin or IVIG in SHAV; do not use outside research/consultation.
• Antibiotics:
  • Only if bacterial meningitis/atypical pneumonia cannot be excluded; discontinue when ruled out.
• Infection control:
  • Arboviral transmission is vectorborne; standard precautions suffice. Emphasize personal protection from bites to prevent further cases. 1

Common pitfalls:

• Delayed escalation in encephalitic presentations; outcome worsens with late airway/ICP management.
• Misattributing febrile illness to SHAV and missing treatable rickettsioses—start doxycycline if clinical suspicion is moderate to high while completing diagnostics, as this reduces mortality. 1

4) Prevention and public health

• Personal protective measures in endemic/exposure settings:
  • Day/night protection against Culicoides and mosquitoes: DEET or picaridin repellents, long sleeves, permethrin‑treated clothing, screened or air‑conditioned lodging. [Arboviral guideline frame.] 1
• Veterinary interface:
  • If local livestock abortion storms or dairy illness occur, notify public health/animal health authorities; SHAV/Simbu circulation may signal human exposure risk. 2, 4, 6

5) When to suspect something else instead

• Hemorrhagic fever or shock: prioritize dengue, RVF, CCHF based on region—higher mortality and specific management implications. 1
• Severe polyarthralgia: consider chikungunya. 1
• Prominent pulmonary edema/shock: think hantavirus cardiopulmonary syndrome; manage with aggressive supportive care and appropriate precautions. 8, 9

Decision algorithm (concise):

• Febrile traveler/exposed to livestock/midges:
  • Check malaria, dengue, chikungunya, rickettsiae first. Start doxycycline if rickettsial suspicion. 1
  • If neuro signs or persistent unexplained fever with relevant exposure:
    • Send orthobunyavirus/Simbu RT‑PCR (blood ± CSF) and serology; obtain convalescent sera; involve public health lab for typing (consider reassortants). 3, 4, 5
    • Manage supportively; escalate for encephalitis. No antivirals. Emphasize vector avoidance. 1

Nuances/contradictions:

• Animal/vectored detections of SHAV are robust and recent, but human disease data are sparse; therefore, act with caution while prioritizing more common, higher‑mortality pathogens first to protect morbidity, mortality, and QOL. 2, 3, 4, 6